Protein-tyrosine phosphatase-1B (PTP1B) negatively regulates insulin and leptin signalling, rendering it an attractive drug target for treatment of obesity-induced insulin resistance.
Introduction
Protein tyrosine phosphatase-1B (PTP1B) is a non-receptor tyrosine phosphatase, identified as an attractive drug target for conditions associated with metabolic syndrome as well as potential anti-cancer therapeutic, due to its diverse involvement in regulation of various cell signalling cascades. Evidence to support the notion that PTP1B inhibition may be beneficial in states of over-nutrition and insulin resistance was demonstrated in mice with a global-(1, 2), as well as tissue-specific-PTP1B deletion (3) (4) (5) (6) .
Insulin resistance in adipose, muscle and liver is exacerbated in obese states, due to the underlying presence of chronic low-grade inflammation and macrophage infiltration into these tissues. White adipose tissue (WAT) from obese subjects contains greater numbers of infiltrating pro-inflammatory macrophages in comparison to lean counterparts, and these cells secrete cytokines such as tumour necrosis factor-alpha (TNFα), interleukin-1 beta (IL1β), and interleukin-6 (IL6), which can impair systemic insulin sensitivity (7) (8) (9) (10) (11) . This process is enhanced further by the release of chemokines, such as monocyte-chemoattractant protein-1 (MCP1), which recruits more activated tissue-macrophages into WAT (12) . Saturated fatty acids are able to directly induce the expression of these pro-inflammatory cytokines via activation of the NF-κB pathway, and the receptor primarily responsible for potentiating this effect has been identified as the macrophage toll-like receptor (TLR)4 (13) . Mice with myeloid-TLR4 deletion are protected against high-fat (HF) diet-induced inflammation, adipose macrophage infiltration and insulin resistance (14) .
It has been postulated that PTP1B may act as a negative regulator of TLR4 signalling in macrophages, since in vitro PTP1B knock-down in the Raw 264.7 macrophage cell line resulted in elevated production of TNFα, IL6 and IFNβ, following challenge with a variety of TLR ligands (15) . PTP1B overexpression in the same cell line, caused a concomitant decrease in pro-inflammatory cytokine production in response to LPS-and palmitatechallenge (15, 16) . Similarly, splenic macrophages isolated from global PTP1B -/-mice were found to be highly sensitive to LPS-induced iNOS expression and nitric oxide production, in addition to elevated interferon gamma (IFNγ)-induced phosphorylation of STAT1 (17) . In the same study, in vivo LPS-challenge increased sensitivity to endotoxic-shock in PTP1B -/-mice, associated with increased systemic production of interleukin-12 (IL12) and IFNγ. However, since these studies were performed in mice with global PTP1B deletion, and PTP1B regulation of cell function/signalling varies in a cell-specific manner (3-6), we set out to definitively establish the in vivo role of macrophage-PTP1B, by assessing the regulation of inflammation and whole body metabolism in LysM-PTP1B knockout mice.
Research Design and Methods
Animal studies. weight recorded weekly. The approximate fatty-acid profile of Adjusted Calories Diet (% total fat) was 28%-saturated, 30%-trans, 28%-monounsaturated (cis) and 14%-polyunsaturated (cis). For endotoxemia experiments, 50-week old chow-fed and HF-fed mice were fasted for 2-hours and injected intraperitoneally with LPS (1 mg/kg, 0.5 mg/kg respectively; Merck). Mice were observed for signs of sepsis, including reduced mobility, fur-ruffling, and conjunctivitis (19) . 24-or 3-hours post-LPS injection (stated in figure legends), mice were sacrificed by cervical dislocation and tissues/blood harvested (3).
Blood analysis. Tail-blood glucose from fasted (5-hours) mice was measured using glucometers (Accu-Check, Burgess Hill, UK) (6). Serum TNFα, IL6, MCP1, insulin, leptin, PAI1, and resistin were measured using adipokine multiplex-kit (Millipore, UK) and serum IL10 levels determined by ELISA (R&D Systems, Minneapolis, USA). Alanine-transferase (ALT) (BioVision) and serum glucose (Thermo Scientific) levels were assayed per manufacturer's instructions. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT)
were performed as described (2, 6) . For hematocrit-level determination, whole-blood was collected in heparinised micro-hematocrit capillary tubes and centrifuged for 3-minutes. The percentage hematocrit value was determined by measuring the length of the red-blood cell layer and calculating as a percentage of the total height of the column sample.
Isolation of T-lymphocytes.
Single-cell suspensions were made from spleens and lymph nodes by pressing through a 70-μm strainer (BD Falcon). After red-blood cell lysis (Sigma), cells were labelled with anti-L3T4 (CD4) microbeads (Milteny Biotec) and sorted using LS-columns (Milteny Biotec).
Isolation and stimulation of bone-marrow-derived-macrophages (BMDMs).
BMDMs were obtained by flushing out femurs and tibiae with sterile PBS (Lonza), as described previously (6) . Mature macrophages were seeded in 6-well tissue-culture plates (1 x 10 6 cells/well) and serum-starved for 16-hours prior to stimulation with 100 ng/ml LPS (InvivoGen), 10 ng/ml IL10 (Peprotech), or 20 ng/ml IL6 (Peprotech).
Cell line work Stable knock-down of PTP1B in RAW 264.7 cells (murinemacrophage cell line) was performed using short-hairpin RNA constructs as previously described (20) Immunoblotting. Cells and tissues were lysed in radioimmunoprecipitation-assay (RIPA) buffer containing fresh sodium-orthovanadate and protease-inhibitors (21). Proteins were separated by 4-12% SDS-PAGE and transferred to nitrocellulose membranes.
Immunoblots were performed using antibodies from Cell Signaling (NEB, Hitchin, UK) (unless stated otherwise) against pERK1/2 MAPK T202/Y204, pIKKα/β S176/S180, IκBα, p- Nitrite-determination. Nitric-oxide production by BMDMs was quantified by determining the concentration of nitrite present in supernatants using Griess-reaction (22) .
Adipose-immunohistochemical staining. Ethanol-fixed, paraffin-embedded adipose tissue sections were stained as previously described (23) , 5% fetal-bovine serum, and 5 mM EDTA. 0.04 ± 0.005 ng/ml vs 0.1 ± 0.03 ng/ml respectively, (P=0.18; 2-tail t-test); IL6: 3.7 ± 0.9 ng/ml vs 14.3 ± 5.3 ng/ml, respectively (P=0.06; 2-tail t-test) (table 2). At 3-hours post-LPS, there was also a trend towards increased IL10 levels in LysM-PTP1B mice (0.89 ± 0.12 ng/ml vs. 0.67 ± 0.03 ng/ml, (P = 0.12; 2-tail t-test) although this was not observed at 24-hours post-LPS (table 2) . Furthermore, levels of hepatic STAT1 and STAT3 phosphorylation were significantly lower in LysM-PTP1B mice, indicative of decreased LPS-induced hepatic-
inflammation (fig 1J and IK).

LysM-PTP1B macrophages exhibit altered cytokine kinetics
To assess whether the anti-inflammatory phenotype observed in LPS-challenged LysM-PTP1B mice is due specifically to the absence of macrophage-PTP1B, isolated
BMDMs were stimulated with 100 ng/ml LPS for varying durations, up to 24-hours in vitro. We found increased levels of phosphorylated-STAT1 alpha and beta isoforms in LysM-PTP1B macrophages treated with LPS for 24-hours ( fig 3A, 3C) , which is in agreement with previous reports and is a likely explanation for the elevated iNOS and nitrite levels produced by these cells (17) . The level of phosphorylated-STAT3 was also significantly increased in LysM-PTP1B cells following 24-hours of treatment with 100 ng/ml LPS ( fig 3B, 3C) . The ability of endogenous IL10 to directly induce STAT3 activation is a likely cause for the heightened levels of phosphorylated-STAT3 observed in PTP1B-deficient macrophages, since the levels of IL10 detected in respective supernatants were also elevated (24) .
Elevations in
To assess this, LysM-PTP1B and control macrophages were stimulated with IL10 for varying durations and levels of STAT3-phosphorylation determined ( fig 3D) . IL6, which also activates STAT3, was used to allow for a direct comparison ( fig 3E) . An elevation in IL10- Since LysM-PTP1B mice were protected from an acute inflammatory challenge, we tested in vivo effects of myeloid-PTP1B deficiency under states of chronic low-grade inflammation, caused by long-term (29 weeks) HFD-feeding (23).
Despite no alterations in body weight (fig 4A) , glucose tolerance tests (GTT) revealed improved ability to clear exogenous glucose in LysM-PTP1B HFD-fed mice ( fig 4B) . The area under the curve (AUC) also confirmed that LysM-PTP1B mice were more glucose tolerant than control mice ( fig 4C) . LysM-PTP1B mice were also more insulin-tolerant with decreased blood glucose levels at 15, 90, and 120 min post-insulin injection ( fig 4D) , and decreased AUC during ITT ( fig 4E) .
Further, acute pro-inflammatory LPS-challenge led to hyperinsulinemia in HFD-fed control mice (75% increase from basal). Strikingly, LysM-PTP1B mice were completely protected against LPS-induced hyperinsulinemia (no increase from basal) ( fig 4F) and post-LPS insulin levels were significantly lower in LysM-PTP1B compared to control mice. Post-LPS blood glucose levels were also lower in LysM-PTP1B mice ( fig 4G) . Additional measures of metabolic parameters and circulating cytokines are shown in tables 1 and 2, respectively.
HFD-fed LysM-PTP1B and control mice were injected with either saline or insulin (10mU/g body weight) and components of the insulin signalling pathway investigated in muscle, liver and WAT. There were no significant differences in insulin-stimulated insulin receptor phosphorylation between the two genotypes in muscle, (fig 4H) , 4N) .
HFD-fed LysM-PTP1B mice have increased circulating IL10 levels, an elevation in spleen cells expressing myeloid markers, and increased levels of splenic phospho-
STAT3.
Basal circulating levels of the anti-inflammatory cytokine IL10 were elevated in HFD-fed LysM-PTP1B compared to control mice ( fig 5A) . Acute LPS-challenge led to an induction of IL10 in both control and LysM-PTP1B mice, which led to a further 120% elevation in IL10 levels in LysM-PTP1B ( fig 5B) . Furthermore, we found a negative correlation between serum IL10 and ALT levels ( fig. 5C ), as well as serum IL10 and insulin levels ( fig 5D) in HFD-mice following LPS-injection, suggesting that elevated circulating IL10 levels are strongly associated with the anti-inflammatory role of myeloid-PTP1B deficiency.
Despite the strong anti-inflammatory phenotype of LysM-PTP1B mice, these mice (but not control mice) developed splenomegaly on HFD ( fig 5E) with a mean spleen weight of 0.48 ± 0.05g (n = 14) compared to 0.14 ± 0.02g (n = 13) (P≤0.0001; 2-tailed T-test) which was also significant when corrected for body weight ( fig 5F) . To assess if these mice were anaemic, hematocrit testing was performed on whole blood and no differences were found between LysM-PTP1B (36.6 ± 1.1 %; n = 9) and control mice (38.9 ± 1.0 %; n = 3). H&E staining of spleen sections revealed unremarkable histology ( fig. 5G ). Spleen size was found to strongly correlate with circulating IL10 levels under basal and LPS-stimulated states ( fig   5H and 5I) . Splenic-IL10 mRNA levels correlated with circulating IL10 levels following LPS-treatment, suggesting that the elevation in systemic IL10 seen in HFD-fed LysM-PTP1B
is, at least in part, spleen-derived ( fig 5J) .
Flow-cytometry analysis of splenocytes established that the percentage of cells
expressing the granulocyte/monocyte marker Gr1, and the monocyte marker Ly6C, were significantly increased in LysM-PTP1B cells compared to controls and a trend for increased expression of Ly6G was noted (P=0.09) ( fig 5K) . There were no alterations in the percentage of cells expressing CD3, CD4, CD8, B220, CD11c, CD11b, F4/80 and MHCII; however, when normalised against total cell number, a significant increase in absolute cell numbers expressing all markers was established for LysM-PTP1B mice compared to controls
(supplementary table 2).
Spleen lysates from HFD-fed LysM-PTP1B mice revealed an increase in the phosphorylation of STAT3α and STAT3β isoforms compared to control lysates (fig L and   5M ). Using antibodies against total STAT3, a significant increase in the alternatively spliced STAT3β isoform was noted in LysM-PTP1B mice ( fig 5L and 5M ). Interestingly, the splenic level of the anti-apoptotic protein BCL2, which is regulated at the gene level by STAT3, was also increased in these mice, which could contribute towards the splenomegaly phenotype observed (fig 5L and 5M) .
Discussion
Previous reports have implicated macrophage-PTP1B in the negative regulation of TLR4-mediated inflammatory signalling; however, these studies have been restricted to in vitro cell line analysis or characterization of responses in PTP1B global knock-out mice (15) (16) (17) 25) . To definitively address the role of macrophage-PTP1B in inflammatory signalling,
we have generated mice with myeloid-specific PTP1B deletion and interrogated their whole body physiology and signalling in isolated macrophages. These mice exhibited an LPStolerant phenotype in vivo, which was mirrored by the attenuation of pro-inflammatory cytokine expression in LPS-treated BMDMs lacking PTP1B in vitro. A likely explanation for the down-regulation of TNFα observed in vitro was the concomitant increase in transcription and secretion of the anti-inflammatory cytokine, IL10. This was further reinforced by heightened levels of phosphorylated-STAT3, which is known to mediate IL10-driven repression of inflammatory targets (26) . A similar increase in phosphorylated-STAT3 was observed when macrophages lacking PTP1B were challenged with IL10, in vitro. The IL10R engage JAK1 and Tyk2 following receptor activation leading to the phosphorylation and activation of STAT3 (27, 28) and since Tyk2 is a known substrate of PTP1B (29), this is a plausible reason for the hyperphosphorylation of STAT3 observed in the absence of PTP1B.
Furthermore, activated STAT3 has been shown to control the expression of the IL10
promoter, leading to a positive feedback mechanism (30) . In summary, the altered cytokine profile displayed by these cells and their increased sensitivity to IL10 may be responsible, at least in part, for the state of LPS-tolerance observed in LysM-PTP1B mice 24-hours after receiving low-dose endotoxin in vivo.
Our in vitro analysis also revealed increased STAT1 phosphorylation, leading to increased iNOS and nitrite production in LPS-treated LysM-PTP1B BMDMs, which is in agreement with previous findings of LPS-treated spleen-macrophages from global knock-out mice (17) . Although heightened levels of NO have been partly implicated as a cause for increased endotoxin sensitivity in PTP1B -/-mice, no such phenotype was observed in LysM-PTP1B mice. These findings do however add to a large body of evidence that links PTP1B to the regulation of JAK-STAT activation (3, 29, (31) (32) (33) (34) .
The anti-inflammatory phenotype observed in endotoxin-challenged LysM-PTP1B mice was similarly replicated in our long-term-HFD-feeding study, which is known to chronically increase plasma-LPS concentration and has thus been termed metabolic endotoxemia (23) . Most remarkably, in vivo LysM-PTP1B mice exhibited increased basaland LPS-induced levels of circulating IL10 compared to control animals, which we found to negatively correlate with insulin and ALT levels. The insulin-sensitizing effect mediated by Increased phosphorylation of splenic STAT3 found in HFD-fed LysM-PTP1B mice, is in agreement with our in-vitro BMDM studies, as well as a recent study confirming STAT3
as a substrate of myeloid-PTP1B (34) , which demonstrated that global-PTP1B-/-mice are protected against experimental colitis due to a STAT3/JAK2-mediated expansion of myeloidderived suppressor cells (MDSCs) (34) . Our data also provides evidence that this mechanism is, at least in part, applicable to the anti-inflammatory phenotype observed in HFD-fed LysM-PTP1B mice. States of chronic inflammation, which could be extended to encompass metabolic endotoxemia, are known to expand immunosuppressive MDSC populations (CD11b+ Gr1+ cells) via elevations in factors including pro-inflammatory cytokines, prostanoids and growth factors that lead to persistent STAT3 activation (43) . In the absence of myeloid-PTP1B we observe increased splenic phospho-STAT3, elevated numbers of splenic cells expressing myeloid markers and marked splenomegaly, which would be indicative of MDSC expansion (43) . In addition to the ability of MDSCs to inhibit T-cell activation (44, 45) and NK-cell tumour cytotoxicity (46), these cells are known to interact with macrophages by secreting elevated levels of IL-10, which promote macrophage polarization towards the M2 macrophage phenotype (47) . It is therefore plausible to postulate that in the absence of myeloid-PTP1B, chronic HFD-feeding leads to a STAT3-dependent expansion of IL-10-secreting splenic MDSCs and possibly M2 macrophages, which alleviate hepatic and adipose inflammation and enhance insulin sensitivity. Figure 6 displays a schematic depicting the postulated mechanism responsible for the beneficial effects observed for HFD-fed LysM-PTP1B mice.
In summary, this study provides evidence that LysM-PTP1B mice exhibit improved glucose tolerance and suppressed inflammatory responses in HFD-fed and endotoxemic mouse models. This is contrary to previous reports that have assigned an anti-inflammatory function to macrophage-PTP1B, and will therefore help allay concerns relating to the application of PTP1B inhibitors in the clinical setting and open up new avenues for the use of PTP1B inhibitors as anti-inflammatory agents.
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